This company has been marked as potentially delisted and may not be actively trading. Miragen Therapeutics (MGEN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MGEN vs. SERA, BDSX, MDXH, XGN, BNR, ENZ, OPGN, BGLC, ACON, and NTRAShould you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include Sera Prognostics (SERA), Biodesix (BDSX), MDxHealth (MDXH), Exagen (XGN), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), OpGen (OPGN), BioNexus Gene Lab (BGLC), Aclarion (ACON), and Natera (NTRA). Miragen Therapeutics vs. Sera Prognostics Biodesix MDxHealth Exagen Burning Rock Biotech Enzo Biochem OpGen BioNexus Gene Lab Aclarion Natera Sera Prognostics (NASDAQ:SERA) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, community ranking, profitability and media sentiment. Do analysts prefer SERA or MGEN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sera Prognostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Miragen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings and valuation, SERA or MGEN? Sera Prognostics has higher earnings, but lower revenue than Miragen Therapeutics. Sera Prognostics is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSera Prognostics$77K1,565.26-$36.24M-$0.99-3.23Miragen Therapeutics$4.46M11.45-$41.87M-$20.09-0.65 Does the media prefer SERA or MGEN? In the previous week, Sera Prognostics' average media sentiment score of 0.00 equaled Miragen Therapeutics'average media sentiment score. Company Overall Sentiment Sera Prognostics Neutral Miragen Therapeutics Neutral Which has more risk and volatility, SERA or MGEN? Sera Prognostics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Do institutionals & insiders have more ownership in SERA or MGEN? 54.6% of Sera Prognostics shares are owned by institutional investors. 15.8% of Sera Prognostics shares are owned by insiders. Comparatively, 1.1% of Miragen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor SERA or MGEN? Miragen Therapeutics received 257 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 70.45% of users gave Miragen Therapeutics an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote. CompanyUnderperformOutperformSera PrognosticsOutperform Votes1038.46% Underperform Votes1661.54% Miragen TherapeuticsOutperform Votes26770.45% Underperform Votes11229.55% Is SERA or MGEN more profitable? Sera Prognostics has a net margin of 0.00% compared to Miragen Therapeutics' net margin of -1,393.50%. Sera Prognostics' return on equity of -51.73% beat Miragen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sera PrognosticsN/A -51.73% -36.94% Miragen Therapeutics -1,393.50%-141.66%-88.74% SummarySera Prognostics beats Miragen Therapeutics on 10 of the 15 factors compared between the two stocks. Remove Ads Get Miragen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGEN vs. The Competition Export to ExcelMetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.08M$2.82B$5.58B$7.57BDividend YieldN/A24.77%5.35%4.04%P/E Ratio-1.2312.9622.9818.19Price / Sales11.45180.58362.8486.44Price / CashN/A57.5638.1634.64Price / Book1.934.206.534.03Net Income-$41.87M-$22.21M$3.21B$247.18M Miragen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGENMiragen TherapeuticsN/A$13.07+4.1%N/A-24.7%$51.08M$4.46M-1.2345High Trading VolumeSERASera Prognostics0.4335 of 5 stars$4.14+9.2%N/A-62.5%$139.82M$77,000.00-4.18120Positive NewsGap DownBDSXBiodesix2.9196 of 5 stars$0.83-1.9%$2.95+255.2%-57.9%$121.24M$71.32M-2.13220Short Interest ↑MDXHMDxHealth2.3304 of 5 stars$1.58-1.3%$6.50+311.4%-48.8%$74.72M$90.05M-1.04300XGNExagen4.6813 of 5 stars$4.05+4.4%$7.50+85.2%+193.4%$72.49M$55.64M-4.31220Short Interest ↓Positive NewsGap DownBNRBurning Rock BiotechN/A$5.67-0.6%N/A-41.1%$58.39M$510.89M-1.891,390Gap DownENZEnzo Biochem0.5586 of 5 stars$0.49+0.8%N/A-74.5%$25.68M$29.09M0.00520Analyst ForecastOPGNOpGenN/A$2.70flatN/A-33.2%$22.56M$2.67M0.00100Analyst ForecastNews CoverageGap DownBGLCBioNexus Gene Lab0.9437 of 5 stars$0.29+1.0%N/A-58.2%$5.12M$9.26M0.0030Positive NewsGap DownACONAclarion2.0892 of 5 stars$0.77+2.7%$435.50+56,458.4%-99.6%$392,000.00$49,289.000.007Stock SplitNews CoverageNTRANatera3.7633 of 5 stars$153.83+1.8%$178.12+15.8%+55.8%$20.80B$1.70B-87.403,020Insider TradeShort Interest ↑News CoveragePositive NewsGap Down Remove Ads Related Companies and Tools Related Companies Sera Prognostics Alternatives Biodesix Alternatives MDxHealth Alternatives Exagen Alternatives Burning Rock Biotech Alternatives Enzo Biochem Alternatives OpGen Alternatives BioNexus Gene Lab Alternatives Aclarion Alternatives Natera Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGEN) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
